Aurobindo Pharma - Details On 483 Issued By U.S. FDA Towards Unit-I: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
The Unit-I of Aurobindo Pharma Ltd. is active pharma ingredient manufacturing unit of cardiovascular, central nervous systems, anti-allergies and non-sterile Ceph products located in Medak, Telangana, India.
As the plant is currently under Warning Letter, U.S. Food and Drug Administration carried out long pending current good manufacturing practice audit in the plant during August 02 to 12, 2021 and concluded with seven observations of Form-483.
While there were no issues of data integrity and repeat observations, its seven observations raised concerns over quality of data maintained at the plant, as Aurobindo Pharma documented outcome of action/tests after a lag.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.